Skip to main content
. Author manuscript; available in PMC: 2021 Nov 8.
Published in final edited form as: Arch Pathol Lab Med. 2019 Nov 13;144(6):725–734. doi: 10.5858/arpa.2019-0241-OA

Table 3.

The Relationships of Community Pathology–Diagnosed Cervical Intraepithelial Neoplasia (CIN) 3 and CIN2, Stratified on p16 Immunohistochemistry (IHC) Result, With Biomarkers of Cervical Cancer Risk: the Biopsy Testing Positive for Human Papillomavirus Type 16 (HPV16), an Antecedent High-Grade Intraepithelial Lesion (HSIL) or More Severe (HSIL+) Cytologic Interpretation, and an Expert Panel (EP) Review Histopathologic Diagnosis of CIN Grade 3 (CIN3) or More Severe (CIN3+) or CIN Grade 2 (CIN2) or More Severe (CIN2+)

Biomarker Result p16 IHC-Negative CIN2 p16 IHC-Positive CIN2 CIN3
N % N % N % P a P trend b
HPV16+ 91 21.41 415 38.18 658 54.47 <.001 <.001
HSIL+ cytologyc 80 21.11 206 21.02 447 42.53 <.001 <.001
EP diagnosis of CIN3+ 22 5.18 249 22.91 789 65.31 <.001 <.001
EP diagnosis of CIN2+ 118 27.76 700 64.40 1064 88.08 <.001 <.001
HPV16+, HSIL+, and/or EP diagnosis of CIN3+ 163 38.35 633 58.23 1038 85.93 <.001 <.001
HPV16+, HSIL+, and EP diagnosis of CIN3+ 3 0.71 27 2.48 192 15.89 <.001 <.001

Below the individual biomarker results, the relationships of the diagnoses with combinations of any (or) or all (and) biomarkers are shown.

a

p16 IHC–positive CIN2 versus CIN3.

b

Trend for p16 IHC–negative CIN2 versus p16 IHC–positive CIN2 versus CIN3.

c

Forty-six p16 IHC–negative CIN2, 107 p16 IHC–positive CIN2, and 157 CIN3 missing antecedent cytology.